The team argues these variations are significant enough to classify them as
An international research team has identified two biologically different forms of type 1 diabetes based on age at diagnosis and immune system activity. The findings come from a large-scale analysis of patient data and biological markers across multiple countries. This discovery could reshape how the condition is understood and treated in the future. The study examined immune responses and genetic profiles in hundreds of individuals diagnosed with type 1 diabetes. Researchers found that those diagnosed before age seven showed a distinct immune pattern compared to those diagnosed after age thirteen. These differences suggest the disease may not be a single condition but rather two separate pathways leading to similar symptoms. Age at Diagnosis Reveals Biological Differences Patients diagnosed in early childhood had higher levels of certain autoantibodies and a more aggressive loss of insulin-producing cells. In contrast, those diagnosed during adolescence displayed a slower progression and different genetic risk factors.
Latest news
Swedish Voters Choose New Parliament as Left-Wing Coalition Projects to Win Majority
Trump Announces End of US Tariff on Irish Whisky
Frances Stonor Saunders, Author of CIA Cultural Espionage Exposé, Dies at 66
Israel and Lebanon to Hold Security Talks in Rome This OctoberThe team argues these variations are significant enough to classify them as distinct disease subtypes. How Might Treatment Change Based on Subtype? Current therapies for type 1 diabetes follow a one-size-fits-all approach, primarily focusing on insulin replacement. If the two forms require different interventions, treatments could be tailored to target the specific immune mechanisms involved. This might include adjusting immunotherapy timing or selecting drugs based on the patient’s biological profile. Frequently Asked Questions What does this mean for people living with type 1 diabetes today? While the findings are promising, they are still based on research data and not yet applied in clinical practice. Patients should continue following their current treatment plans under medical supervision. Could this lead to a cure for type 1 diabetes? Not directly, but understanding the disease’s heterogeneity may improve prevention strategies and increase the chances of developing more effective, personalized therapies in the long term.
Will genetic testing be used to distinguish between the two types? The study suggests genetic and immunological markers could help differentiate the forms, but further validation is needed before such tests become standard in diagnosis or treatment planning.
